A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic HBV infection
History of lamivudine (LVD) treatment, and lamivudine resistance (LVDr), receiving LVD at screening visit
Compensated liver function
HBV DNA ≥ 172,000 IU/mL
Hepatitis B e-antigen (HBeAg)-positive or HBeAg-negative
You may not be if
Evidence of decompensated cirrhosis
Coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis D virus (HDV)
Recent history of pancreatitis
Serum alpha fetoprotein \> 100 ng/mL
Except lamivudine, any prior therapy with nucleoside or nucleotide analogue antiviral agents with activity against hepatitis B
Clareo Health | A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection
